IRulya Therapeutics Inc. (IRLA) stock
Close on Nov 12, 2026Market cap $40.46MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $40.46M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -116.17%
Fundamentals
- Net income
- -$92.48M
- EPS, diluted
- -$16.80
- Free cash flow
- -$47.00M
- Book value per share
- -$5.76
- Diluted shares
- 6M
Trading
- Next earnings
- Q3 FY2026, expected soon
- Previous close
- $38.33
- Open
- $37.98
- Day's range
- $35.00 – $41.72
- Volume
- 138,307
- Average volume (20 days)
- 106,857
- Beta (5 years)
- 1.00
- 52-week range
- $15.10 – $909.98
- RSI (14 days)
- 61.7
- Volatility (1 year)
- 355.4%
- Relative volume
- 3.45×
- WACC
- 9.9%
Market cap history
Month-end market cap since 2019, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | IRLA | S&P 500 | Difference | IRLA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +22.8% | -2.7% | +25.5 pts | ||
| 3 months | +27.3% | -1.7% | +29.0 pts | ||
| Year to date | -94.1% | +11.9% | −106.0 pts | ||
| 1 year | -88.4% | +12.0% | −100.4 pts | ||
| 3 years | -77.9% | +78.2% | −156.1 pts | -39.6% | +21.2% |
| 5 years | -98.6% | +73.2% | −171.8 pts | -57.4% | +11.6% |
| 10 years | -97.9% | +309.6% | −407.6 pts | -32.1% | +15.1% |
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases IRulya Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- News
- Results
- News
- News
About IRulya Therapeutics
Biological Products, (No Diagnostic Substances)
Quince Therapeutics, Inc. is a biotechnology company that historically focused on developing therapies for rare diseases by utilizing a patient's own red blood cells for drug delivery. The company's proprietary Autologous Intracellular Drug Encapsulation (AIDE) technology platform consists of an automated drug and device combination designed to encapsulate drugs into autologous red blood cells to enhance biodistribution, extend half-life, and improve tolerability across small molecules and biologics. Its lead asset was eDSP, which encapsulated dexamethasone sodium phosphate for the treatment of ataxia-telangiectasia. Following disappointing results in its Phase 3 NEAT trial, the company discontinued further clinical development of eDSP and ceased research activities.
Company profile, executives and historyIRulya Therapeutics stock: common questions
What is IRulya Therapeutics's stock price?
IRLA closed at $39.78 on Nov 12, 2026, up 3.78% on the day. Over the past 52 weeks it traded between $15.10 and $909.98.
What is IRulya Therapeutics's market cap?
IRulya Therapeutics was worth $40.46M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is IRLA's P/E ratio?
IRulya Therapeutics lost money over fiscal 2025 (diluted EPS -$16.80), so it has no meaningful P/E ratio.
Does IRulya Therapeutics pay a dividend?
No. IRulya Therapeutics has not paid a cash dividend over the last twelve months.
When does IRulya Therapeutics report earnings next?
IRulya Therapeutics's Q3 FY2026 results are due soon; the company has not yet filed them with the SEC.
How has IRLA stock performed over the past year?
Including dividends, IRLA returned -88.4% over the past year, against +12.0% for the S&P 500.
Who are IRulya Therapeutics's competitors?
Companies most similar to IRulya Therapeutics by business, industry and size include TIL, SGMOQ, SLDB, FDMT, SANA.
See a number that looks wrong?